"We are particularly pleased that this brief, six-week, six-injection regimen can have lasting positive effects for more than one season of ragweed exposure," said Peter Creticos, M.D., associate professor of medicine at Johns Hopkins and principal investigator of the study. "These studies represent a major advance in the development of new treatments for allergic disease, especially when compared with conventional allergy treatments, which can take years to be effective," he added.
The new treatment is an allergy vaccine created by attaching immune-system-boosting molecules, or oligonucleotides, to Amb 1 a, the major ragweed protein responsible for allergic reactions.
Creticos will present the new findings of the Johns Hopkins study on March 11 at a special symposium on "Allergy Therapeutics" at the 60th annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI).
The observer-blinded, placebo-controlled Phase II study evaluated adult volunteers who had a history of fall seasonal hayfever and had skin test reactions to ragweed pollen. Using a vaccine developed by scientists at University of California, San Diego, and produced by Dynavax Technologies Corporation of Berkeley, Calif., Johns Hopkins investigators gave patients the new treatment before the 2001 ragweed season. These patients were followed for their clinical improvement throughout the 2001 and 2002 ragweed seasons wit
Contact: Trent Stockton
Johns Hopkins Medical Institutions